ArticleKidney diseases (Basel, Switzerland)
Clinicopathological Characteristics and Outcomes of Patients with Crescentic Lupus Nephritis.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Crescentic lupus nephritis (cLN) is an uncommon and severe phenotype in LN with limited data on outcomes and relevant risk factors. Methods: Eighty-three cases of biopsy-proven LN with ≥50% crescents were included. Another 83 non-crescentic LN patients with <50% crescents (non-cLN) were matched through propensity score as the control group. Results: The cLN patients accounted for 4.03% of LN patients in renal biopsy. Compared with age- and gender-matched non-cLN patients, cLN patients had higher serum creatinine levels, anti-neutrophil cytoplasmic antibody (ANCA) positivity rates, activity index, and chronic index scores, while the positive rate of anti-dsDNA antibodies and complement 3 were lower. The cLN patients exhibited a lower treatment response rate than matched non-cLN patients (34.8% vs. 64.3%, Conclusions: cLN patients had worse treatment response and renal outcomes than non-cLN but the mortality risk was similar. The presence of wire-loop lesions and renal tubular atrophy >50% on renal biopsy may predict ESRD in cLN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.